Hsa-circ-0064636 regulation of the target gene VDAC1/UBE4A by hsa-miR-326/hsa-miR-503-5 in osteosarcoma

Guohua Yan
Guangxi Medical University

Hanji Huang
Guangxi Medical University

Kanglu Li
Guangxi Medical University

Mingjun Zheng
Guangxi Medical University

Jiagang Qin
Guangxi Medical University

Dejie Lu
Guangxi Medical University

Ying Chen
Guangxi Medical University

Xiaofei Cui
Guangxi Medical University

Si He
Guangxi Medical University

Jianwen Cheng (📧 1730054162@qq.com)
Guangxi Medical University First Affiliated Hospital  https://orcid.org/0000-0003-1321-5791

Research Article

Keywords: circRNA, miRNA, osteosarcoma, VDAC1, UBE4A

DOI: https://doi.org/10.21203/rs.3.rs-305653/v1

License: ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Circular RNAs (circRNAs) are a subclass of noncoding RNAs that play a critical role in the regulation of gene expression in eukaryotic organisms. Recent studies have revealed the critical role of circRNAs in cancer progression. Yet, little is not well understood of hsa-circ-0064636 in osteosarcoma (OS).

Methods: The differential expression of hsa-circ-0064636 in OS cell lines was verified by quantitative real-time PCR (qRT-PCR). Differentially expressed mRNAs and miRNAs were screened in OS mRNA and miRNA expression datasets. miRNAs that interacted with hsa-circ-0064636 were predicted by RNAhybrid, TargetScan and miRanda. and were further detected using RNAhybrid, TargetScan and miRanda. miRWalk, miRMap, and miRNAMap were used to perform target gene prediction on the intersected miRNAs to construct a circ-miRNA-mRNA interactor network. The target genes were then subjected to survival analysis using PROGgeneV2, which resulted in a circ-miRNA-mRNA interaction subnetwork with prognostic impact.

Results: The qRT-PCR experiments successfully verified that hsa-circ-0064636 was significantly overexpressed in the OS cell line. Hsa-mir-326(miR-326) and hsa-mir-503-5p(miR-503-5p) are target miRNAs of hsa-circ-0064636 in the target genes obtained from the miR-326 and miR-503-5p screens. UBE4A and VDAC1 had a significant effect on prognosis. UBE4A is a target gene for miR-326, while VDAC1 is a target gene for miR-503-5p.

Conclusion: hsa-circ-0064636 may be involved in OS development through acting as a sponge to inhibit miR-326 and miR-503-5p, thus regulating the expression of VDAC1 and UBE4A.

1. Introduction

Osteosarcoma (OS) is one of the most common primary malignant bone tumors, most commonly seen in children and adolescents, and is characterized by high aggressiveness, high metastatic potential, rapid progression, and chemoresistance. In the past few decades, with extensive resection surgery and multidrug adjuvant chemotherapy, 5-year survival rates have improved to 70–80%. Regrettably, the 5-year survival rate for patients with chemical resistance is significantly reduced to less than 20% due to poor sensitivity to chemotherapy. OS patients may be better off with additional therapies, such as small molecule targeted agents, but these strategies are not currently making breakthroughs in clinical trials. Therefore, there is an urgent need for further research in the search for new OS therapies, especially complex gene regulatory networks.

In recent decades, studies have successively identified new classes of noncoding RNAs (ncRNAs), for instance circular RNAs (circRNAs), microRNAs (miRNAs), and long ncRNAs (IncRNAs). They all have different regulatory functions, can effectively regulate essential protein effectors of cellular function and play an important role in the development of osteosarcoma. Among them, circRNA is a highly stable
and conserved special RNA with covalent closed-loop properties that is not easily degraded by endonucleases and is widely found in various tissues and organs. A growing body of research shows that circRNAs are widely participation in disease development in many ways and have important roles in cancer. However, the potential molecular mechanisms and regulatory relationships of circRNAs in osteosarcoma are still not defined.

In the present study, we mainly focused on the differential expression of hsa-circ-0064636 in OS and further studied its regulatory mechanism by bioinformatics to clarify its expression and prognostic significance and to provide a new experimental basis and research ideas for future OS molecular marker studies.

2. Materials And Methods

2.1. Materials and equipment. Human normal osteoblasts hFOB1.19 and OS cell lines (HOS, SJSA-1 and MG63) were purchased from Shenzhen Haodi Huatuo Biotechnology Co. Scientific (Shenzhen, China). The TRizol kit was purchased from Invitrogen (California, USA). The cDNA reverse transcription kit, SYBR green PCR mix, was purchased from TaKaRa Biotechnology (Tokyo, Japan). The real-time quantitative PCR instrument (LightCycler® 96) was purchased from Roche (Basel, Switzerland).

2.2. Cell culture. hFOB1.19 cells were cultured with DMEM/F12 medium containing 10% fetal bovine serum with the addition of G418 (0.3 mg/mL) as well as penicillin (100 U/mL) and streptomycin (100 U/mL). OS cell lines were all cultured with DMEM/F12 medium containing 10% fetal bovine serum with the addition of streptomycin (100 U/mL) and penicillin (100 U/mL). All cells were incubated in 5% CO₂ at 37°C in a constant temperature incubator. Fresh complete medium was replaced every 2 or 3 days for further incubation, and when the cell density reached 90% or more, cells were then passaged to the next generation at a ratio of 1:3.

2.3. RNA Extraction and qRT-qPCR. Total cellular RNA was extracted by TRizol, and cDNA was synthesized using a reverse transcription kit. qRT-qPCR was performed using SYBR green PCR mix and divergent primers from hsa-circ-0064636 with the following reaction conditions: pre-denaturation at 95°C for 10 min, denaturation at 95°C for 15 s, annealing at 60°C for 30 s, and 45 cycles. The glyceraldehyde phosphate dehydrogenase (GAPDH) and U6 expression was used as a control. The relative expression of the final screened genes was calculated by a comparative method \(2^{-\Delta \Delta C_{t}}\). The primers required in this study are listed in Table 1.

2.4. CircRNA-miRNA-mRNA network construction. The miRNAs interacting with hsa-circ-0064636 were predicted via the circRNA target miRNA prediction tools RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/mahybrid/), TargetScan (http://www.targetscan.org/) and miRanda (http://www.microrna.org/microrna/home.do), which intersected to identify miRNAs that were simultaneously targeted by the four prediction tools. For miRNA targeting, the gene prediction tools RNAhybrid, TargetScan, miRanda, miRWalk (http://zmf.umm.uni-
2.5 Wayne diagramming. Wayne diagrams are plotted using the R package 'Venn'.

2.6 Differential expression analysis. The miRNA expression dataset GSE65071 (9 normal samples, 14 OS samples) and the mRNA expression dataset GSE1608816 (9 normal samples, 14 OS samples) were downloaded from the GENE EXPRESSION OMNIBUS (https://www.ncbi.nlm.nih.gov/geo/, GEO) database and the Bioconductor affy was used. The Limma package was used to identify differentially expressed genes between normal and tumor samples. log2|foldchange(FC) | > 1 and adj.P-values < 0.05 were considered to be statistically significantly different, and the resulting differentially expressed genes were used for volcano mapping.

2.7. Survival analysis. PROGgeneV2 (http://genomics.jefferson.edu/proggene) is a tool that can be used along with publicly available data to investigate the prognostic significance of genes. The previously obtained common target genes were entered into a database, the dataset for osteosarcoma was selected, and the overall survival map was constructed based on the median expression of a given gene that could be classified into high and low expression groups (Kaplan-Meier, KM plots). PROGeneV2 was used for hypothesis testing using the SURVIVAL package for R. The data were analyzed using the log-rank test. Statistical analysis was performed using the log-rank test, and the threshold for a meaningful survival prognosis was a p-value < 0.05. Based on the survival analysis, a new circRNA-miRNA-mRNA visual regulatory subnetwork was obtained.

2.8 Statistical analysis. GraphPad Prism 8 was used to statistically analyze the experimental data, and the statistical test data were normally distributed. A two-tailed value of p<0.05 was considered statistically significant, and a t-test was used for comparisons between the two groups.

3. Result

3.1 Analysis of variance expression. In the miRNA expression profile data, 114 miRNAs were upregulated and 117 miRNAs were downregulated in osteosarcoma, and the differential expression volcanoes of miRNAs were plotted (Figure 1A). The differential analysis of mRNA expression spectrum data yielded 716 mRNAs for downregulated genes and 1924 mRNAs for downregulated genes, and the differential expression volcanoes of mRNAs were mapped (Figure 1B).

3.2 Hsa_circ_006463 targeting miRNA prediction. In order explore the regulatory mechanism of hsa_circ_006463 in OS species, hsa_circ_006463 target miRNAs were predicted by four databases. TargetScan, miRanda and RNAhybrid predicted 498, 965 and 226 target miRNAs, respectively, while
differential analysis yielded 88 target miRNAs. All four intersections were used to obtain common target miRNAs for miR-326 and miR-503-5p (Figure 2).

3.3 Prediction and analysis of miRNA targeted genes. The mechanism of the regulatory action of hsa-miR-326 and miR-503-5p in OS was studied and the possible binding of target genes was further predicted. miR-326 target genes were predicted by miRWalk, miRanda, miRMap, miRNAmap, RNAhybrid, and TargetScan databases; respectively, 5071, 3364, 6616, 6716, 16373, and 4830 target genes were obtained. Intersection with the 1924 upregulated differential genes obtained from the analysis yielded 31 target genes, which were plotted on a Wayne diagram and labeled with the names of these 31 target genes (Figure 3A). miR-503-5p target genes were analyzed by miRWalk, miRanda, miRMap, miRNAmap, RNAhybrid and TargetScan databases, which yielded 2034, 844, 6692, 1496, 12416 and 2196 target genes, respectively. These were intersected with the 1924 upregulated differential genes from the previous analysis to obtain 31 target genes, which were plotted on a Wayne plot and labeled with the six target gene names (Figure 3B).

3.4 CircRNA-miRNA-mRNA network construction. Six databases were used for hsa-miR-326 and miR-503-5p to predict binding targets and differential gene heptad intersections to obtain 31 and 9 target gene relationships, respectively, to construct relationship networks (Figure 4). hsa-circ-0064636 may be targeted to bind miR-326 and miR-503-5p. The target genes that miR-326 targets and binds to are TNC, HNRNPA2B1, ATXN1, DPYSL2, RGS3, UBE4A, MRC2, PSMC1, FOXO3, SRRM1, SAMD4A, MYO1D, ADAM17, PDIA4, VGLL4, FYN, NFATC3, VCL, SPAG9, MED13L, RAI14, MYOF, NDEL1, TUBB, ALPL, USP11, CEP350, LSM1, GOLPH3, C9orf3 and CUX1 (31 target genes in total). miR-503-5p target-binding target genes were PSMD7, INSR, PTPN12, TCF7L2, VDAC1 and TPM1 (6 target genes in total).

3.5 Survival analysis. Overall survival curves were obtained for a total of 31 of the 37 target genes, and details are shown in Table 2. Unfortunately, HNRNPA2B1, FOXO3, MYOF, C9orf3, and CUX1 could not be retrieved in the database. In the survival analysis of 31 target genes, only two differences were significant (<0.05), namely, UBE4A and VDAC1, and their survival curves were obtained, as shown in Figure 5. UBE4A is a target gene of miR-326, while VDAC1 is a target gene of miR-503-5p.

3.6 CircRNA to miRNA to mRNA network construction with prognostic impact significance. Based on the original circRNA-miRNA-mRNA ceRNA interaction axes, the mRNA retained only the two target genes (UBE4A and VDAC1) with prognostic impact on survival (circRNA and miRNA were also retained) and removed the other target genes, thus constructing a new subnetwork with prognostic implications, shown in Figure 6.

3.7 Validation of differential expression in OS cell lines. The differential expression of hsa-circ-0064636 was first detected by qRT-PCR in human OS cell lines (HOS, SJSA-1, MG63, U2OS) and human osteoblast cell lines (hFOB1.19). The results showed that the expression of hsa-circ-0064636 was significantly upregulated in the human OS cell line compared to osteoblasts (Figure 6A).
4. Discussion

OS is one of the common malignant tumor of bone, what's more the treatment of OS is still a major problem for human health. The current treatment for OS is mainly surgery and chemotherapy, but the prognosis of patients is still not satisfactory. Previous studies have shown that many genes are associated with the development and progression of OS, however the emphasis has been on protein-coding genes or miRNAs\textsuperscript{17}. The molecular mechanisms of OS are still unknown, as well as in the recent past, some noncoding RNAs have been shown to play an important role in the development of OS\textsuperscript{18,19}. For example, it has been found that the IncRNA(TMPO-AS1), by regulating the miR-199a-5p to WNT7B axis, acts as a ceRNA that promotes osteosarcoma tumorigenesis\textsuperscript{20}. miRNA-1236-3p is significantly overexpressed in the OS, thereby inhibiting cell proliferation and inducing apoptosis by targeting KLF8\textsuperscript{21}.

In contrast to other non-coding RNAs, for instance IncRNAs as well as miRNAs, circRNAs are highly conserved and highly stable in mammalian cells. These properties make circRNAs potentially ideal biomarkers and potential therapeutic targets\textsuperscript{22}. In recent years, a growing body of research reveals that the important role of circRNAs in different biological processes, especially in tumorigenesis, development, and metastasis, such as gastric cancer\textsuperscript{23}, colorectal cancer\textsuperscript{24}, lung cancer\textsuperscript{25}, and cervical cancer\textsuperscript{26}. A previous study reported that circTADA2A is differentially expressed between OS cell lines and corresponding noncancer cell lines\textsuperscript{27}. Nevertheless, There are also many circRNAs whose role in the development of osteosarcoma is still largely unknown. In this study, we focused on the significantly upregulated expression of hsa-circ-0064636 in OS cell lines and normal tissue cell lines and further predicted the regulatory network between its targeted regulatory miRNAs and corresponding target genes.

In this study, miR-326 and miR-503-5p were predicted to be the target miRNAs of hsa-circ-0064636 by multiple databases of circRNA-miRNA interactions. miR-326 and hsa-miR-503-5 were also used in the GSE65071 dataset and were underexpressed in the osteosarcoma samples compared to normal samples in the difference-in-differences analysis to verify their expression in osteosarcoma. As mentioned in a previous study, hsa-circ-0064636 is significantly up-regulated in OS, regulates down-regulation of miR-326 and promotes cervical cancer progression through up-regulation of ELK1. MiR-326 overexpression transfection experiments verified that it can lead to inhibition of proliferation and invasion and induce apoptosis and autophagy in cervical cancer cells\textsuperscript{28}. MiR-326 is also significantly underexpressed in prostate cancer\textsuperscript{29} and correlated with prognosis. However, miR-503-5p has been reported to inhibit tumorigenesis, angiogenesis, and lymphangiogenesis in colon cancer through direct downregulation of VEGF-A\textsuperscript{30}. and in hepatocellular carcinoma studies, miR-503-5p has been reported to regulate epithelial to mesenchymal transformation, metastasis, and prognosis of hepatocellular carcinoma cells through inhibition of WEE1\textsuperscript{31}. It follows that miR-326 and miR-503-5p play a key role in cancer suppression in many cancers, as well as their expression is low in cancer. Therefore, hsa-circ-0064636 may lead to the development of OS by suppressing the expression of miR-326 and miR-503-5p in OS. In the existing reports, no query has been made about miR-326 and miR-503-5p in OS.
This study also further used the miRNA prediction mRNA database with analysis of significantly differentially expressed genes in OS to screen the potential target genes of miR-326 and miR-503-5p to obtain a circRNA-miRNA-mRNA ceRNA Interaction Network. On the basis of this, we further screened the mRNAs with prognostic impact to obtain a circRNA-miRNA-mRNA regulatory subnetwork. ube4A was a potential direct target of miR-326, and VDAC1 was a potential target of miR-503-5p. We also found significant prognostic differences between UBE4A and VDAC1 in the survival analysis of OS patients. The results of survival analysis plots showed the prognosis of UBE4A and VDAC1 was significantly worse in the high expression group compared to the low expression group.

UBE4A is belonging to the U-box ubiquitin ligase class of enzymes. The encoded protein is involved in polyubiquitin chain assembly and plays a key role in chromosome condensation and polyubiquitination segregation via securin. Autoantibodies against the encoded protein Potential to become a marker for scleroderma and Crohn's disease\textsuperscript{32,33}. UBE4A is significantly upregulated in comparison between ovarian plasmatic cystic carcinoma and adjacent normal tissues. The VDAC1 voltage-dependent anion channel protein is a major component of the outer mitochondrial membrane\textsuperscript{34}. VDAC1 is expressed in all compartments including mitochondria, the plasma membrane and other cells. The protein regulates major metabolic and energetic functions of the cell, including \( \text{Ca}^{2+} \) homeostasis, oxidative stress, and mitochondria-mediated apoptosis. Because overexpression of VDAC1 triggers cell death, it may be related to the destruction of nerve cells\textsuperscript{35}. VDAC1 was identified as a tumor promoter in cervical cancer, as well as knock-down of VDAC1 in cervical cancer cell lines increase the rate at which apoptosis occurs, which was partially reversed by overexpression of VDAC1\textsuperscript{36}.

Importantly, we verified by qRT-PCR that hsa-circ-0064636, VDAC1 and UBE4A were highly expressed in osteosarcoma cell lines, and miR-326 and miR-503-5p were lowly expressed in osteosarcoma cell lines. The results of qRT-PCR were consistent with the results of our bioinformatics analysis. The disadvantage is that the combination of the regulatory network finally obtained still needs to be further verified in the subsequent experiments.

5. Conclusion

The target binding miRNAs of hsa-circ-0064636 were miR-326 and miR-503-5p. Further predicting the mRNAs to which the miRNAs might bind and taking the intersection results with differentially expressed mRNAs showed that miR-326 had 31 potential targets. miR-503-5p had six potential binding coding genes, and a circRNA-miRNA-mRNA regulatory network was derived according to this. Survival analysis results showed that UBE4A and VDAC1 had significant impact significance, resulting in a survival-significant subregulatory network of hsa-circ-0064636-miR-326 /miR-503-5p-UBE4A/VDAC1. It was verified by qRT-PCR experiments that hsa-circ-0064636, UBE4A and VDAC1 is significantly differentially overexpressed in OS cell lines while miR-326 and miR-503-5p were under-expressed in osteosarcoma cell lines. In conclusion, hsa-circ-0064636 may be involved in OS development by acting as a sponge, suppressing miR-326 and miR-503-5p to Facilitate up-regulation of VDAC1 and UBE4A.
Abbreviations

GEO: Gene Expression Omnibus
MiRNA: MicroRNA
OS: Osteosarcoma
CircRNAs: Circular RNAs
HR: Hazard ratio
IncRNA: long ncRNAs
qRT-PCR: quantitative real-time PCR

Declarations

Ethics approval and consent to participate

Ethics approval was obtained from the Ethics Committee of Guangxi Medical University (Nanning, China).

Acknowledgments and Funding

This research was supported by the National Natural Science Foundation of China (NO. 81960400).

Authors’ Contributions

Guohua Yan and Hanji Huang are equal contributors to this research. Guohua Yan and Hanji Huang designed the research program and wrote this text. Kanglu Li, Mingjun Zheng, Jiagang Qin, Dejie Lu, Ying Chen, Xiaofei Cui and Si He conducted the research and analyzed the data. Jianwen Cheng revised the manuscript and sought financial support.

Availability of data and materials

The GEO miRNA dataset generated and analyzed during the current study is available under dataset accession number GSE65071, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65071. The GEO mRNA dataset generated and analyzed during the current study is available under dataset accession number GSE16088, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16088. All other datasets generated during the current study are available from the corresponding author on reasonable request. Also, data used to support the results of this study, including qRT-PCR experiments, copies are available upon request from the corresponding authors.

Conflicts of Interest
The authors declare that no conflicts of interest exist in this study.

Consent for publication

The manuscript has not been published or presented elsewhere, nor has it been considered by other journals.

References

1. Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. *Front. Oncol.* 8, (2018).

2. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.

3. Otoukesh B, Boddouhi B, Moghtadaei M, Kaghazian P, Kaghazian M. Novel molecular insights and new therapeutic strategies in osteosarcoma. Cancer Cell Int. 2018;18:158.

4. Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. *Curr Opin Pediatr.* 2016;28:26–33.

5. Wang K, Jiang W, Cheng C, Li Y, Tu M. Pathological and Therapeutic Aspects of Long noncoding RNAs in osteosarcoma. *Anticancer Agents Med Chem* (2017) doi:10/ghfwqv.

6. Jones KB, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. *Cancer Res.* 2012;72:1865–77.

7. Memczak S, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature.* 2013;495:333–8.

8. Wilusz JE, Sharp PA. Molecular biology. A circuitous route to noncoding RNA. *Science.* 2013;340:440–1.

9. Yang F, et al. High-Throughput Sequencing and Exploration of the IncRNA-circRNA-miRNA-mRNA Network in Type 2 Diabetes Mellitus. *Biomed Res Int* 2020, 8162524 (2020).

10. Rehmsmeier M, Steffen P, Höchsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. *RNA.* 2004;10:1507–17.

11. Agarwal V, Bell GW, Nam J-W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 4, (2015).

12. Riffo-Campos ÁL, Riquelme I, Brebi-Mieville P. Tools for Sequence-Based miRNA Target Prediction: What to Choose? *Int J Mol Sci* 17, (2016).

13. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. *J Biomed Inform.* 2011;44:839–47.

14. Vejnar CE, Blum M, Zdobnov EM. miRmap web: Comprehensive microRNA target prediction online. *Nucleic Acids Res.* 2013;41:W165–8.
15. Hsu S-D, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 2008;36:D165–9.
16. Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. BMC Cancer. 2014;14:970.
17. Yang J, Wang N. Analysis of the molecular mechanism of osteosarcoma using a bioinformatics approach. Oncol Lett. 2016;12:3075–80.
18. Assumpção MB, et al. High-Throughput miRNA Sequencing Reveals a Field Effect in Gastric Cancer and Suggests an Epigenetic Network Mechanism. Bioinform Biol Insights. 2015;9:111–7.
19. Gu W, et al. Identification of Gastric Cancer-Related Circular RNA through Microarray Analysis and Bioinformatics Analysis. Biomed Res Int 2018, 2381680 (2018).
20. Cui H, Zhao J. LncRNA TMPO-AS1 serves as a ceRNA to promote osteosarcoma tumorigenesis by regulating miR-199a-5p/WNT7B axis. J Cell Biochem. 2020;121:2284–93.
21. Sun Y, et al. Upregulated miRNA-1236-3p in osteosarcoma inhibits cell proliferation and induces apoptosis via targeting KLF8. Eur Rev Med Pharmacol Sci. 2019;23:6053–61.
22. Jeck WR, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19:141–57.
23. Li R, et al. CircRNA: a rising star in gastric cancer. Cell Mol Life Sci. 2020;77:1661–80.
24. Ju H-Q, et al. A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO Mol Med. 2019;11:e10168.
25. Zong L, et al. Increased expression of circRNA_102231 in lung cancer and its clinical significance. Biomed Pharmacother. 2018;102:639–44.
26. Song T, et al. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075. J Cell Physiol. 2019;234:14296–305.
27. Wu Y, Circular. RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. 20 (2019).
28. Tang Q, Chen Z, Zhao L, Xu H. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. Aging. 2019;11:9982–99.
29. Moya L, Meijer J, Schubert S, Matin F, Batra J. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis. Int J Mol Sci 20, (2019).
30. Wei L, Sun C, Zhang Y, Han N, Sun S miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-A. Gene Ther (2020) doi:10/ghf25t.
31. Jiang S-P, Li Z-R. MiR-503-5p regulates cell epithelial-to-mesenchymal transition, metastasis and prognosis of hepatocellular carcinoma through inhibiting WEE1. Eur Rev Med Pharmacol Sci. 2019;23:2028–37.
32. Sakiyama T, Fujita H, Tsubouchi H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn’s disease. Inflamm Bowel Dis. 2008;14:310–7.
33. Contino G, et al. Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues. Gene. 2004;328:69–74.

34. Yi X, et al. A Ca2 + chelator ameliorates chromium (VI)-induced hepatocyte L-02 injury via down-regulation of voltage-Dependent anion channel 1 (VDAC1) expression. Environ Toxicol Pharmacol. 2017;49:27–33.

35. Shoshan-Barmatz V, Nahon-Crystal E, Shteinfer-Kuzmine A, Gupta R. VDAC1, mitochondrial dysfunction, and Alzheimer's disease. Pharmacol Res. 2018;131:87–101.

36. Zhang C, et al. Proteomics-based identification of VDAC1 as a tumor promoter in cervical carcinoma. Oncotarget. 2016;7:52317–28.

Tables

Table 1. qRT-qPCR primer sequences.

| Gene                  | Sequence(5’ to 3’)                  |
|----------------------|-------------------------------------|
| has_circ_0064636- LEFT | GCTTCCCCTGTCTCCACATA               |
| has_circ_0064636- RIGHT| ATGTCCAAAGGGTTTCAGCA               |
| GAPDH - LEFT         | ACCCTGTTGCTGTAGCCA                 |
| GAPDH – RIGHT        | CCACCTCCTCCACCTTTGAC               |
| UBE4A – LEFT         | GTCCACGTGCAAGCTGATCT               |
| UBE4A -RIGHT         | AGTTACATCTTCAAAAATGGGCTCC          |
| VDAC1 – LEFT         | GGAAGGCAGAAGATGGCTGT               |
| VDAC1-RIGHT          | GTCCACGTGCAAGCTGATCT               |

Table 2. Target gene survival analysis results
| gene  | HAZARD RATIO | LCI (95%) | UCI(95%) | P VALUE   |
|-------|--------------|-----------|----------|-----------|
| TNC   | 0.8          | 0.59      | 1.09     | 0.1608707 |
| ATXN1 | 1.06         | 0.45      | 2.51     | 0.896135  |
| DYSPL2| 0.72         | 0.31      | 1.66     | 0.4461738 |
| RGS3  | 0.59         | 0.21      | 1.61     | 0.3011995 |
| UBE4A | 1.6          | 1         | 2.57     | 0.0489371 |
| MRC2  | 0.81         | 0.38      | 1.73     | 0.5945315 |
| PSMC1 | 0.38         | 0.1       | 1.4      | 0.1471227 |
| SRRM1 | 1.11         | 0.35      | 3.51     | 0.8532273 |
| SAMD4A| 0.75         | 0.25      | 2.28     | 0.610971  |
| MYO1D | 0.76         | 0.4       | 1.45     | 0.4085244 |
| ADAM17| 0.4          | 0.06      | 2.86     | 0.3620074 |
| PDIA4 | 0.81         | 0.38      | 1.74     | 0.5882791 |
| VGLL4 | 1.03         | 0.46      | 2.27     | 0.9508824 |
| FYN   | 1.66         | 0.7       | 3.95     | 0.251584  |
| NFATC3| 4.94         | 0.76      | 32.03    | 0.09380364009382 |
| VCL   | 0.6          | 0.29      | 1.24     | 0.1688802 |
| ALPL  | 1.07         | 0.83      | 1.39     | 0.5919638 |
| TUBB  | 1.59         | 0.92      | 2.78     | 0.0992659 |
| RAI14 | 0.33         | 0.16      | 0.68     | 0.0026146 |
| LSM1  | 1.58         | 0.78      | 3.22     | 0.2074225 |
| GOLPH3| 1.54         | 0.94      | 2.5      | 0.0836026 |
| PSMD7 | 0.7          | 0.32      | 1.54     | 0.3788017 |
| INSR  | 0.13         | 0.01      | 1.79     | 0.1255452 |
| PTPN12| 1.62         | 0.89      | 2.94     | 0.1136242 |
| TCF7L2| 3.99         | 0.79      | 20.11    | 0.0939648 |
| VDAC1 | 4.09         | 1.26      | 13.29    | 0.0191903 |
| TPM1  | 0.73         | 0.47      | 1.16     | 0.1857696 |

Figures
Figure 1

Differential gene expression volcano plot, with red representing up-regulated genes and green representing down-regulated genes. (A) miRNA differential expression volcano plot, where the positions of miR-326 and miR-503-5p are labeled. (B) mRNA differential expression volcano plot with the positions of VDAC1 and U8E4A labeled.
Figure 2

Schematic representation of hsa-circ-0064636 targeted miRNAs. TargetScan, miRanda, and RNAhybrid database predicted hsa-circ-0064636 target miRNAs and miRNA Wayne plots were derived from the differential analysis, with the two common miRNAs labeled on the right side of the figure.

Figure 3
MiRNA target gene predictions and differential gene Wayne plots. (A) Wayne plot of the intersection of miR-326 using six databases to predict binding target genes and differentially expressed genes. The 31 miR-326 target mRNA names are shown on the right side of (A). (B) Six databases were used for miR-503-5p to predict the intersection of binding target genes, and differentially expressed genes are shown in a Wayne diagram. The names of the six miR-503-5p target mRNAs are shown on the right side of (B).

Figure 4

CircRNA-miRNA-mRNA ceRNA regulatory network starting with hsa-circ-0064636. Red circle represents circRNA, blue triangle represents miRNA, and yellow square represents mRNA.
Figure 5

Survival curves of target genes were plotted using Kaplan-Meier curves on the PROGeneV2 online platform, with red lines representing high expression of the genes and green lines representing low expression of the genes. (A) Survival curve analysis of VDAC1. (B) Survival curve analysis of UBE4A.
Figure 6

CircRNA-miRNA-mRNA ceRNA regulatory network construction according to target genes with prognostic impact significance. (A) Circles in red represent circRNAs, triangles in blue represent miRNAs, and squares in yellow represent mRNAs. (B-F) Differential expression of Has-circ-0064636/ hsa-miR-326/ hsa-miR-503-5p/ UBE4A and VDAC1 in OS cell lines compared to hFOB1.19 verified by qRT-PCR. *: p<0.05.